scholarly journals Dosimetric comparison of prostate radiotherapy between pelvic node-positive and node-negative patients

2021 ◽  
Vol 19 (4) ◽  
pp. 1009-1014
Author(s):  
S.B. Zincircioglu ◽  
M.H. Dogan ◽  
M.A. Kaya ◽  
F. Teke ◽  
◽  
...  
Keyword(s):  
Node Negative ◽  
Prostate Radiotherapy ◽  
Dosimetric Comparison ◽  
Pelvic Node ◽  
Node Positive

Pelvic node control in patients with locally advanced uterine cervical cancer treated with concurrent chemoradiotherapy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 16018-16018
Author(s):  
T. Toita ◽  
Y. Nagai ◽  
W. Tamaki ◽  
K. Ogawa ◽  
S. Gibo ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Concurrent Chemoradiotherapy ◽  
Response Analysis ◽  
High Dose ◽  
Tumor Diameter ◽  
Cervical Tumor ◽  
Node Negative ◽  
Nodal Recurrence ◽  
Pelvic Node ◽  
Node Positive

16018 Background: To evaluate pelvic node control in cervical cancer patients treated with concurrent chemoradiotherapy (CCRT) without surgical resection. Methods: Ninety-six patients (stage IB2, 3; IIA, 2; IIB, 49; IIIA, 1; IIIB, 40; IVA, 1) with uterine cervical squamous cell carcinoma treated with CCRT were analyzed. Cervical tumor diameter and pelvic node status were assessed by MRI. The median maximum tumor diameter was 58 mm (range, 36–86 mm). Thirty-four patients had positive pelvic nodes (= 10 mm in shortest diameter). The largest diameter of the positive nodes ranged from 10–50 mm (median, 18 mm). All patients received CDDP (20 mg/m2 for 5 days every 21 days), pelvic external beam RT (PERT), and high-dose-rate intracavitary brachytherapy (HDR-ICBT). The planned RT schedule consisted of PERT with 40 Gy/20 fractions (frs) followed by HDR-ICBT with 18–24 Gy/3–4 frs and PERT with 10 Gy/5 frs using a midline block. Thirty of thirty-four node-positive patients received boost RT (6–10 Gy/3–5 frs) to involved nodes. The dose from HDR-ICBT to the pelvic nodes was estimated at a point 6 cm lateral to the midline at the level of the vaginal fornix. Doses of ERT and HDR-ICBT were simply summed and used for pelvic node dose-response analysis. The median total dose was 60 Gy (range, 52–64 Gy) for positive nodes and 54 Gy (range, 51–55 Gy) for negative nodes. Median follow-up of the surviving 79 patients was 41 months (range, 8–98 months). Results: Four-year overall survival (OAS), pelvic control (PC), and distant metastasis-free (DMF) rates for all 96 patients were 79%, 90%, and 79%, respectively. Four-year OAS, PC, and DMF rates for node-positive/node-negative patients were 60%/89% (P=0.002), 82%/95% (P=0.08), and 66%/86% (P=0.008), respectively. Pelvic nodal recurrence was observed in 4 patients. One patient developed isolated pelvic node recurrence while the other 3 had concurrent recurrences at other sites, including 1 with a cervical tumor and 2 with cervical tumor and distant metastases. Nodal recurrence rates by largest diameter were 1/62 for node-negative patients, 1/14 for nodes 10–14 mm, 0/13 for nodes 15–29 mm, and 2/7 for nodes = 30 mm. Conclusions: Pelvic nodal metastases < 30 mm were well controlled by CCRT without surgical resections using RT dose delivered. No significant financial relationships to disclose.

Axillary Reverse Mapping: A Prospective Study in Women with Clinically Node Negative and Node Positive Breast Cancer

2013 ◽  
Vol 20 (10) ◽  
pp. 3303-3307 ◽  
Author(s):  
Carol Connor ◽  
Marilee McGinness ◽  
Joshua Mammen ◽  
Lori Ranallo ◽  
Stephanie LaFaver ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prospective Study ◽  
Node Negative ◽  
Axillary Reverse Mapping ◽  
Node Positive ◽  
A Prospective Study ◽  
Reverse Mapping ◽  
Positive Breast Cancer

scholarly journals Consensus transcriptomic profiles can be utilised to differentiate node negative and node positive colorectal cancer

2013 ◽  
Vol 11 (8) ◽  
pp. 600
Author(s):  
John Hogan ◽  
Cormac O'Connor ◽  
A. Aziz ◽  
Michael O'Callaghan ◽  
Conor Judge ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Node Negative ◽  
Node Positive

Detection of Isolated Tumor Cells in Bone Marrow Is an Independent Prognostic Factor in Breast Cancer

2003 ◽  
Vol 21 (18) ◽  
pp. 3469-3478 ◽  
Author(s):  
G. Wiedswang ◽  
E. Borgen ◽  
R. Kåresen ◽  
G. Kvalheim ◽  
J.M. Nesland ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Prognostic Factor ◽  
Tumor Cells ◽  
Vascular Invasion ◽  
Independent Prognostic Factor ◽  
Histologic Grade ◽  
Separate Analysis ◽  
Node Negative ◽  
Node Positive

Purpose: This study was performed to disclose the clinical impact of isolated tumor cell (ITC) detection in bone marrow (BM) in breast cancer. Patients and Methods: BM aspirates were collected from 817 patients at primary surgery. Tumor cells in BM were detected by immunocytochemistry using anticytokeratin antibodies (AE1/AE3). Analyses of the primary tumor included histologic grading, vascular invasion, and immunohistochemical detection of c-erbB-2, cathepsin D, p53, and estrogen receptor (ER)/progesterone receptor (PgR) expression. These analyses were compared with clinical outcome. The median follow-up was 49 months. Results: ITC were detected in 13.2% of the patients. The detection rate rose with increasing tumor size (P = .011) and lymph node involvement (P < .001). Systemic relapse and death from breast cancer occurred in 31.7% and 26.9% of the BM-positive patients versus 13.7% and 10.9% of BM-negative patients, respectively (P < .001). Analyzing node-positive and node-negative patients separately, ITC positivity was associated with poor prognosis in the node-positive group and in node-negative patients not receiving adjuvant therapy (T1N0). In multivariate analysis, ITC in BM was an independent prognostic factor together with node, tumor, and ER/PgR status, histologic grade, and vascular invasion. In separate analysis of the T1N0 patients, histologic grade was independently associated with both distant disease-free survival (DDFS) and breast cancer–specific survival (BCSS), ITC detection was associated with BCSS, and vascular invasion was associated with DDFS. Conclusion: ITC in BM is an independent predictor of DDFS and BCSS. An unfavorable prognosis was observed for node-positive patients and for node-negative patients not receiving systemic therapy. A combination of several independent prognostic factors can classify subgroups of patients into excellent and high-risk prognosis groups.

Dye-guided sentinel lymphadenectomy in clinically node-negative and node-positive breast cancer patients

Breast Cancer ◽  
1998 ◽  
Vol 5 (4) ◽  
pp. 381-387 ◽  
Author(s):  
Masakuni Noguchi ◽  
Koichiro Tsugawa ◽  
Futoshi Kawahara ◽  
Etsuro Bando ◽  
Koichi Miwa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Sentinel Lymphadenectomy ◽  
Node Positive ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document